International Journal of Celiac Disease
ISSN (Print): 2334-3427 ISSN (Online): 2334-3486 Website: http://www.sciepub.com/journal/ijcd Editor-in-chief: Samasca Gabriel
Open Access
Journal Browser
Go
International Journal of Celiac Disease. 2016, 4(2), 38-39
DOI: 10.12691/ijcd-4-2-7
Open AccessEditorial

Is Enzyme Supplementation Effective Strategy to Reduce the Burden of Gluten Free Diet in Celiac Disease?

Aaron Lerner1,

1B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Pub. Date: May 28, 2016

Cite this paper:
Aaron Lerner. Is Enzyme Supplementation Effective Strategy to Reduce the Burden of Gluten Free Diet in Celiac Disease?. International Journal of Celiac Disease. 2016; 4(2):38-39. doi: 10.12691/ijcd-4-2-7

Abstract

Several strategies have been considered for enzymatic detoxification of dietary gluten and to reduce immunogenisity of gliadin peptides. An enzymatic therapy using enterically coated tablets containing caricain (Gluteguard), originated from a papaya, on celiac disease patients challenged with gluten was reported. Glut guard was able to protect these patients from adverse symptoms being induced by gluten challenge. The advantages of the fruit originated preparation are: it does not contain living microbes or bacterial purified or engineered products. It can be considered as a preventive therapy and further step in the future therapeutical strategy race for the celiac affected population benefits.

Keywords:
celiac disease enzyme supplementation gluten gluten free diet microbial transglutaminase therapy

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Cornell HJ, Czyzewska A, Macrae FA, Rydzewska G, Nasierowska-Gutmejer A, Bednarczuk A, Stelmasiak T. The Effect of Enzyme Supplementation on Symptoms and Duodenal Histology in Celiac Patients. International Journal of Celiac Disease 2016;4(2):40-47.
 
[2]  www.patents.justia.com/assignee/glutagen-pty-ltd.
 
[3]  Lerner A. New Therapeutic Strategies for Celiac Disease. Autoimmun Rev 2010;9:144-147.
 
[4]  Lerner A. [Potential therapeutic strategies in celiac disease]. Harefuah 2012;151:358-361.
 
[5]  Lerner A. Novel therapeutic strategies for celiac disease. AgroFood industry hi-tech. European Journal of Nutraceuticals & Functional Foods. 2013;24:16-20.
 
[6]  Vanga RR, Kelly CP. Novel therapeutic approaches for celiac disease. Discov Med. 2014;17:285-293.
 
[7]  Rashtak S, Murray JA. Review Article: Celiac Disease, New Approaches to Therapy. Aliment Pharmacol Ther. 2012; 35: 768-781.
 
[8]  Di Cagno R, De Angelis M, Auricchio S, et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 2004;70:1088-1096.
 
[9]  Stenman SM, Lindfors K, Venäläinen JI, Hautala A, Männistö PT, Garcia-Horsman JA, Kaukovirta-Norja A, Auriola S, Mauriala T, Mäki M, Kaukinen K. Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells. Clin Exp Immunol. 2010;161:242-249.
 
[10]  Lerner A, Matthias T. Food Industrial Microbial Transglutaminase in Celiac Disease: Treat or Trick. International Journal of Celiac Disease 2015;3(1):1-6.
 
[11]  Helmerhorst EJ, Wei G. Experimental Strategy to Discover Microbes with Gluten-degrading Enzyme Activities. Proc SPIE Int Soc Opt Eng. 2014 May 5; 9112.
 
[12]  Lerner A, Matthias T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev 2015;14:479-89.
 
[13]  Lerner A, Matthias T. Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutr Rev 2015;73:544-552.
 
[14]  Lerner A, Matthias T. Microbial transglutaminase is a potential environmental inducer of celiac disease. In: From Autoantibody Research to Standardized Diagnostic Assays in the Management of Human Diseases. Volume 10th, Eds: K Conrad, Chan EKL, Andrade LEC, Steiner G, Pruijn GJM, Y Shoenfeld. 12th symposium on autoantibodies, 23-26.9.15, Dresden, Germany. Page 227-233, Pabst Science Publishers, Lengerich, Germany, e-pub.
 
[15]  Lerner A, Aminov R, Matthias T. Dysbiosis may trigger autoimmune diseases via inappropriate posttranslational modification of host proteins. Front Microbiol. 2016;7:84.